Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Google Secures Pentagon AI Deal for Classified Projects 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
ZUG, Switzerland, Feb. 5, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will webcast a live fireside chat, featuring Thomas Meyer, Chairman and CEO, at the 2016 Leerink Global Healthcare Conference on Thursday, February 11, 2015, at 8:30 a.m. EST from the Waldorf Astoria Hotel in New York. The webcast will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com).
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Auris Medical Leerink Conference Presentation http://hugin.info/160190/R/1984071/727288.pdf
HUG#1984071
CONTACTS: Auris Medical contacts:
Company: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94,
[email protected]
Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685,
[email protected]
